Autoimmune Rheumatic Disease
Cabaletta Bio Inc. focuses on systemic lupus erythematosus, including severe autoimmune manifestations associated with lupus nephritis and broader systemic inflammation.
- Systemic lupus erythematosus
- Lupus nephritis
- Autoantibody-mediated disease
The sponsor’s research interest in this area centers on B cell-driven immune dysregulation and organ-involving lupus activity.
Idiopathic Inflammatory Myopathy
The company also studies idiopathic inflammatory myopathy, including dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, and juvenile idiopathic inflammatory myopathy.
- Dermatomyositis
- Anti-synthetase syndrome
- Immune-mediated necrotizing myopathy
- Juvenile idiopathic inflammatory myopathy
These programs reflect interest in muscle inflammation, systemic autoimmune disease, and associated extramuscular involvement.
Cell-based Immunotherapy
Cabaletta Bio Inc. is engaged in research on autologous CD19-specific chimeric antigen receptor T cells for autoimmune disease.
- CD19-directed CAR T-cell therapy
- Autologous cell therapy
- Immune reset approaches
This area highlights a therapeutic emphasis on targeted immune-cell modification in conditions driven by pathogenic B cells.
Inflammatory Disease Safety and Tolerability
The sponsor’s active studies include evaluation of safety, tolerability, and adverse events in patients with active autoimmune disease.
- Safety assessment
- Tolerability monitoring
- Adverse event surveillance
These clinical interests are concentrated in high-burden inflammatory disorders requiring precise immune-targeted intervention.
